Intellia Therapeutics, Inc. (NASDAQ:NTLA) Shares Sold by Orchard Capital Management LLC

Orchard Capital Management LLC lowered its stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 1.3% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 170,006 shares of the company’s stock after selling 2,310 shares during the quarter. Orchard Capital Management LLC’s holdings in Intellia Therapeutics were worth $3,805,000 at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of NTLA. Blue Trust Inc. lifted its holdings in Intellia Therapeutics by 1,664.3% in the second quarter. Blue Trust Inc. now owns 1,482 shares of the company’s stock worth $33,000 after purchasing an additional 1,398 shares during the period. First Horizon Advisors Inc. lifted its holdings in Intellia Therapeutics by 22.1% in the second quarter. First Horizon Advisors Inc. now owns 2,604 shares of the company’s stock worth $58,000 after purchasing an additional 472 shares during the period. GAMMA Investing LLC lifted its holdings in Intellia Therapeutics by 1,322.0% in the second quarter. GAMMA Investing LLC now owns 2,645 shares of the company’s stock worth $59,000 after purchasing an additional 2,459 shares during the period. EntryPoint Capital LLC lifted its holdings in Intellia Therapeutics by 61.1% in the first quarter. EntryPoint Capital LLC now owns 4,122 shares of the company’s stock worth $113,000 after purchasing an additional 1,563 shares during the period. Finally, AdvisorNet Financial Inc lifted its holdings in Intellia Therapeutics by 63.5% in the second quarter. AdvisorNet Financial Inc now owns 5,100 shares of the company’s stock worth $114,000 after purchasing an additional 1,980 shares during the period. Institutional investors and hedge funds own 88.77% of the company’s stock.

Intellia Therapeutics Trading Up 1.8 %

NASDAQ NTLA opened at $22.93 on Friday. The stock’s 50-day moving average price is $23.34 and its two-hundred day moving average price is $24.24. The company has a market cap of $2.21 billion, a PE ratio of -4.28 and a beta of 1.77. Intellia Therapeutics, Inc. has a 1 year low of $19.21 and a 1 year high of $34.94.

Intellia Therapeutics (NASDAQ:NTLA) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($1.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.23) by ($0.29). The business had revenue of $7.00 million during the quarter, compared to analysts’ expectations of $19.68 million. During the same quarter in the previous year, the firm posted ($1.40) EPS. The company’s revenue for the quarter was down 48.5% on a year-over-year basis. Research analysts forecast that Intellia Therapeutics, Inc. will post -5.19 EPS for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have commented on NTLA. Royal Bank of Canada reiterated an “outperform” rating and issued a $54.00 price target on shares of Intellia Therapeutics in a research report on Thursday. Stifel Nicolaus dropped their price target on shares of Intellia Therapeutics from $80.00 to $64.00 and set a “buy” rating on the stock in a research report on Wednesday, September 11th. Canaccord Genuity Group reiterated a “buy” rating and issued a $73.00 price target on shares of Intellia Therapeutics in a research report on Thursday, June 27th. Evercore ISI upgraded shares of Intellia Therapeutics to a “strong-buy” rating in a research report on Friday, August 9th. Finally, JPMorgan Chase & Co. dropped their price target on shares of Intellia Therapeutics from $61.00 to $55.00 and set an “overweight” rating on the stock in a research report on Monday, August 12th. One research analyst has rated the stock with a sell rating, four have given a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $61.77.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.